HDAC3 activity is required for initiation of leukemogenesis in acute promyelocytic leukemia
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A pro-oncogenic role of HDAC3 has been identified in leukemogenesis.
“A pro-oncogenic role of HDAC3 has also been identified in leukemogenesis.”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Mehdipour et al., 2017
In acute promyelocytic leukemia, HDAC3 contributes to the repressive influence of PML-RARα.
“In acute promyelocytic leukemia (APL), HDAC3 contributes to the repressive influence of the oncogenic fusion protein PML-RARα.”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Mehdipour et al., 2017
Down-modulation or inhibition of Hdac3 supported differentiation of PML-RARα-expressing cells.
“Moreover, down-modulation of Hdac3 or its inhibition supported the differentiation of PML-RARα-expressing cells (Mehdipour et al., 2017).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Mehdipour et al., 2017
The citation lists haven’t been fetched yet
References 12 · Cited by 25
- Authors
- Mehdipour, P., Santoro, F., Botrugno, O. A., Romanenghi, M., Pagliuca, C., Matthews, G. M., Johnstone, R. W., & Minucci, S.
- Affiliations
- European Institute of Oncology (IT)
- IRCCS Ospedale San Raffaele (IT)
- Dana-Farber Cancer Institute (US)
- The University of Melbourne (AU)
- University of Milan (IT)
- Corresponding author
- Santoro, F
- Johnstone, R W
- Minucci, S
- Venue
- Leukemia
- Published
- 2017-01-24
- Volume
- 31
- Issue
- 4
- Pages
- 995-997
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2577089244
- Cited by
- 25
- References
- 12
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 1 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 2 · 2017: 1
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Leukemia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fondazione Italiana per la Ricerca sul Cancro
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- HDAC3, histone deacetylase, acute promyelocytic leukemia, leukemogenesis, leukemia initiation, histone deacetylase inhibitors
- MeSH terms
- Histone Deacetylase 3, Animals, Hematopoietic Stem Cells, Histone Deacetylases, Humans, Mice, Inbred C57BL, Neoplasm Proteins, Leukemia, Promyelocytic, Acute, Mice, Carcinogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
